Mysimba is new diet pills that first became available for sale in 2017. Mysimba tablets are already available in Spain and will be supplied to pharmacies in most European countries before the end of 2017.
The action mechanism of Mysimba tablets differs from that of other obesity drugs, available in Europe. Therefore, they will certainly open the way to a successful weight loss for thousands of obese Europeans, who fail to reduce their weight through other methods of fighting obesity.
The uniqueness of Mysimba tablets is that they contain two active ingredients at once:
8 mg *
It reduces cravings for delicious, sweet, high-calorie food.
90 mg *
Suppresses appetite and stimulates energy expenditure.
Thanks to these effects, Mysimba helps to:
- Successfully modify eating behavior
- Quickly get rid of bad eating habits
- Achieve a sustained and long-term weight loss.
*Dosage of the active ingredient in one tabletThe efficacy of Mysimba is proven by the results of clinical studies that involved more than 4,500 obese men and women.
The results of the studies demonstrated that with the regular use of Mysimba tablets for 1 year:
Researchers have proven that in patients, who take Mysimba twice daily, decrease:
Body fat percentage and waist circumference.
Cardiometabolic risk factors.
Levels of cholesterol and triglycerides in the blood.
Children and adolescents did not take part in Mysimba trials, and today they are not being prescribed this drug for weight loss.
In 2013, however, the EMA’s Pediatric Committee decided to allow the developer of Mysimba to begin a clinical trial that involves children.If such studies succeed, and the safety of Mysimba for the health of obese children will be proven, this drug will certainly be approved for drug therapy for childhood and/or adolescent obesity.
Today, Mysimba is prescribed to adult men and women for the treatment of:
Obesity (BMI of 30 and higher)
Overweight ** (BMI from 27 and higher)
** In the presence of cardiometabolic risk factors.
Mysimba tablets should be used only for assistive drug therapy for obesity, in combination with a low-calorie diet and regular physical activity.
Mysimba sales are allowed in all EU countries, as well as the European countries that are not EU members.
Developer & Manufacturer
The formula prototype for the diet pills Mysimba was developed by:
- Physiologist Michael Cowley.
- Doctor of Medical Sciences Eckard Weber.
In 2002, Dr. Weber and Michael Cowley founded Orexigen Company. For more than 10 years, Weber, Cowley and other Orexigen employees have been studying the combined impact of Naltrexone and Bupropion active ingredients over the mechanisms that regulate hunger and satiety.
After a successful completion of laboratory, preclinical and clinical studies, Orexigen Company patented the new drug, based on Naltrexone and Bupropion, and applied for its approval in:
- The European Medicines Agency (EMA)
- The US Food and Drug Administration (FDA).
In the USA, the combined weight loss drug Naltrexone/Bupropion was registered under the trademark Contrave.
In Europe, the tablets for the anti-obesity treatment, based on Naltrexone/Bupropion were registered under the brand Mysimba.
After studying the results of clinical trials on Mysimba (Contrave) – the FDA and the EMA:
- Confirmed the efficacy and safety of this drug for weight loss.
- Approved it for the treatment of overweight and obesity in adults over 18 years of age.
Suppliers & Distributors
The developer and manufacturer of Mysimba/Contrave diet pills is Orexigen. Yet, this company has no experience in pharmaceutical products commercialization. Therefore, it is forced to enter into commercial agreements with other companies that will distribute Mysimba and Contrave on the international market.
The largest European supplier of Mysimba is Valeant (and its subsidiary, PharmaSwiss). Valeant obtained the rights to commercialize Mysimba (Naltrexone/Bupropion) in more than 20 countries, including the countries of:
Bosnia and Herzegovina
Estonia.Turkey.Canada.Australia, New Zealand.
Less large European suppliers of Mysimba are the companies:
UK and Ireland
In the first quarter of 2017, Mysimba/Contrave medications have already been approved for the treatment of obesity in more than 40 countries.
However, retail sales are only launched in some of them, including:
- The USA (in 2014)
- South Korea (in 2016)
- Spain (in 2017).
The molecular formula of Mysimba (Naltrexone 8 mg / Bupropion 90 mg) is protected by a patent:
- Until 2024 in the EU
- Until 2027 in the US.
Until 2024, Orexigen and its partners will own an exclusive European patent for medicines, based on the combination of the active ingredients Naltrexone/Bupropion.
Therefore, in the medium term, only branded Mysimba tablets will be sold in Europe, and the generic versions of this drug will not be available.
If you want to buy Mysimba, ask your doctor if these diet pills are sold in your country of residence.
Before planning a visit to the doctor:
- Check out the Summary Of Product Characteristics for Mysimba
- Find the answers to frequently asked questions about Mysimba
- Make sure that Mysimba tablets are not contraindicated for you.
If you planned to buy Mysimba, and this drug is not available for sale in your city, you can find it in online pharmacies. Before you buy Mysimba on the Internet, compare the prices for these diet pills in various online pharmacies and familiarize yourself with the terms of their delivery.
You can get all the necessary information about the sale and delivery of Mysimba to your region of residence from the pharmacist of an online pharmacy.